[« back]
Press Release 17.09.2008
mtm laboratories launches CINtec? Cytology kit in Europe with extended clinical claims for cervical cancer diagnosis
Pivotal trial data shows comparable sensitivity and superior specificity in detecting High Grade Disease in equivocal/low grade Pap Test results vs. HPV testing
Heidelberg, Germany; September 17, 2008. mtm laboratories, a fully integrated cancer diagnostics company with proprietary products marketed globally, today announced the launch of the CE-labeled CINtec? Cytology kit with extended claims for the diagnosis of cervical cancer in Europe. The clinical claims are derived from the outcome of a recent pan-European pivotal study involving pathologists and cytotechnologists from France, England, Spain, Italy and Germany.
Ruediger Ridder, CSO of mtm laboratories, commented:
"Equivocal or mild results such as those examined in the study are clinically relevant since a portion of these actually harbour high grade disease, the immediate pre-cursor to Cervical Cancer, and as such cannot be ignored. However, it is costly and inefficient to treat or manage all of the cases based on the initial cytology finding, which is why a more accurate biomarker-based test such as CINtec? Cytology is needed to pinpoint those cases where there is high grade disease."
Bob Silverman, CEO of mtm laboratories, commented:
"Approximately 6-8% of Pap Test results will be equivocal or mildly abnormal. While the majority of these diagnoses are benign, 10-15% of these cases will harbour high grade disease creating a clinical dilemma for clinicians. The results of this trial demonstrate that CINtec Cytology can more accurately identify those women with high grade disease than managing these cases with HR-HPV testing. This is a major advance in cervical cancer screening, and for the women participating in screening programs."
The CINtec? Cytology Kit is an immuno-cytochemistry assay for the qualitative detection of the p16INK4a antigen on cervical cytology preparations. It is intended to be used as an aid in the identification of women with underlying high-grade cervical intraepithelial lesions in the sub-group of patients with a Pap cytology result of ASC-US (atypical squamous cells of undetermined significance) or LSIL (low grade intraepithelial lesion).
mtm's CE-labeled CINtec? Cytology kit with extended claims will be marketed solely outside of the U.S.
Disclaimer: This IVD product and the use presented herein has not been cleared or approved by authorities in the United States including the United States Food and Drug Administration.
mtm laboratories AG is an ISO 9001 and ISO 13485 certified developer and manufacturer of In-Vitro Diagnostic Devices (IVDD) for use in the early detection and diagnosis of cervical cancer. The Company operates on a global basis with the headquarter in Heidelberg, Germany and subsidiaries in the United States, France, Italy, Spain and Japan. Further information can be found at: www.mtmlabs.com
Further Information:
Bob Silverman
CEO
mtm laboratories AG
t: +1 508 366 8334
e: contact@mtmlabs.com
Dr. Douglas Pretsell
Account Director, Munich Bureau Chief
College Hill
t : +49 (0)89 57 00 18 06
e: douglas.pretsell@collegehill.com
Notes for editors:
The CINtec? family of diagnostic products
mtm's family of products is based on mtm's proprietary E6H4TM antibody clone which was specifically developed for immunochemistry applications in cervical histology and cytology specimens. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. The over-expression of this biomarker is directly correlated to the oncogenic activity of High Risk Human Papilloma Virus (HR-HPV) that marks the generation of cervical cancer. These biomarker-based diagnostic assays hold the promise to bring high levels of sensitivity and specificity towards the detection of high grade cervical disease in adjunctive uses with conventional technologies.
The CINtec? immunoassays are validated to provide a sensitive and specific method for the detection of p16INK4a in cervical tissues. The currently marketed CINtec? In-vitro Diagnostics (IVDs) have been developed for application on:
CINtec? products are available on a global basis through mtm's direct operations and distributors.
Press Release 17.09.2008
mtm laboratories launches CINtec? Cytology kit in Europe with extended clinical claims for cervical cancer diagnosis
Pivotal trial data shows comparable sensitivity and superior specificity in detecting High Grade Disease in equivocal/low grade Pap Test results vs. HPV testing
Heidelberg, Germany; September 17, 2008. mtm laboratories, a fully integrated cancer diagnostics company with proprietary products marketed globally, today announced the launch of the CE-labeled CINtec? Cytology kit with extended claims for the diagnosis of cervical cancer in Europe. The clinical claims are derived from the outcome of a recent pan-European pivotal study involving pathologists and cytotechnologists from France, England, Spain, Italy and Germany.
Ruediger Ridder, CSO of mtm laboratories, commented:
"Equivocal or mild results such as those examined in the study are clinically relevant since a portion of these actually harbour high grade disease, the immediate pre-cursor to Cervical Cancer, and as such cannot be ignored. However, it is costly and inefficient to treat or manage all of the cases based on the initial cytology finding, which is why a more accurate biomarker-based test such as CINtec? Cytology is needed to pinpoint those cases where there is high grade disease."
Bob Silverman, CEO of mtm laboratories, commented:
"Approximately 6-8% of Pap Test results will be equivocal or mildly abnormal. While the majority of these diagnoses are benign, 10-15% of these cases will harbour high grade disease creating a clinical dilemma for clinicians. The results of this trial demonstrate that CINtec Cytology can more accurately identify those women with high grade disease than managing these cases with HR-HPV testing. This is a major advance in cervical cancer screening, and for the women participating in screening programs."
The CINtec? Cytology Kit is an immuno-cytochemistry assay for the qualitative detection of the p16INK4a antigen on cervical cytology preparations. It is intended to be used as an aid in the identification of women with underlying high-grade cervical intraepithelial lesions in the sub-group of patients with a Pap cytology result of ASC-US (atypical squamous cells of undetermined significance) or LSIL (low grade intraepithelial lesion).
mtm's CE-labeled CINtec? Cytology kit with extended claims will be marketed solely outside of the U.S.
Disclaimer: This IVD product and the use presented herein has not been cleared or approved by authorities in the United States including the United States Food and Drug Administration.
mtm laboratories AG is an ISO 9001 and ISO 13485 certified developer and manufacturer of In-Vitro Diagnostic Devices (IVDD) for use in the early detection and diagnosis of cervical cancer. The Company operates on a global basis with the headquarter in Heidelberg, Germany and subsidiaries in the United States, France, Italy, Spain and Japan. Further information can be found at: www.mtmlabs.com
Further Information:
Bob Silverman
CEO
mtm laboratories AG
t: +1 508 366 8334
e: contact@mtmlabs.com
Dr. Douglas Pretsell
Account Director, Munich Bureau Chief
College Hill
t : +49 (0)89 57 00 18 06
e: douglas.pretsell@collegehill.com
Notes for editors:
The CINtec? family of diagnostic products
mtm's family of products is based on mtm's proprietary E6H4TM antibody clone which was specifically developed for immunochemistry applications in cervical histology and cytology specimens. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. The over-expression of this biomarker is directly correlated to the oncogenic activity of High Risk Human Papilloma Virus (HR-HPV) that marks the generation of cervical cancer. These biomarker-based diagnostic assays hold the promise to bring high levels of sensitivity and specificity towards the detection of high grade cervical disease in adjunctive uses with conventional technologies.
The CINtec? immunoassays are validated to provide a sensitive and specific method for the detection of p16INK4a in cervical tissues. The currently marketed CINtec? In-vitro Diagnostics (IVDs) have been developed for application on:
- cervical biopsies (CINtec? Histology) and
- cervical cytology preparations such as smears and liquid based cytology samples (CINtec? Cytology)
CINtec? products are available on a global basis through mtm's direct operations and distributors.
® mtm laboratories AG, all rights reserved